Bartosz Hudzik/LinkedIn
Feb 11, 2026, 16:08
Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Clinical trials to watch in 2026 — a cardiovascular lens
Nature Medicine highlights 11 trials poised to shape medicine in 2026. In cardiology, two stand out:
- Ziltivekimab – targeting the IL-6 inflammatory pathway to reduce residual inflammatory risk in atherosclerosis and CKD, moving beyond lipid-only prevention.
- Pelacarsen – a first-in-class antisense therapy for lipoprotein(a), tackling one of the most important genetically driven and previously untreatable CV risk factors.
Both are Phase 3 programs with the potential to redefine precision prevention.
2026 may be the year cardiovascular medicine shifts from risk markers to causal, target-specific therapies.”
More posts featuring Bartosz Hudzik on Hemostasis Today.
-
Feb 11, 2026, 15:57Alan Nurden: Looking Beyond Bleeding in VWD
-
Feb 11, 2026, 15:56Samin Mohsenian: I Have Successfully Defended My PhD on Rare Bleeding and Coagulation Disorders
-
Feb 11, 2026, 15:52Amaliris Guerra: What’s The Most Effective Way to Evaluate and Select The Right Mentor?
-
Feb 11, 2026, 15:20Alfredo Lourenco: How to Prevent Hemolysis During Blood Collection
-
Feb 11, 2026, 15:12Pradeep Natarajan: The AHA Scientific Statement on Clonal Hematopoiesis and CVD Led by June-Wha Rhee
-
Feb 11, 2026, 14:45Jeff June: Stroke Care Isn’t Broken, It’s Under-Informed
-
Feb 11, 2026, 11:07Nathan Connell: 100 Years of von Willebrand Disease – From the Åland Islands to Precision Care
-
Feb 11, 2026, 10:55Record-Breaking Abstract Submissions for ISTH 2026 Congress
-
Feb 11, 2026, 10:51Isidora Laur Vuković: Fantastic Blend of Learning and Relationship-Building at EAHAD 2026